Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer


A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed By DD Paclitaxel (DD AC?P); DD AC Followed By DD Paclitaxel Plus Gemcitabine (DD AC?PG)


Drugs used in chemotherapy, such as docetaxel, doxorubicin , cyclophosphamide, paclitaxel, and gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any remaining tumor cells.


This randomized phase III trial is studying three different combination chemotherapy regimens and comparing how well they work in treating women who have undergone surgery for node-positive breast cancer.

Study Status: Active, not recruiting


Condition Intervention Phase
Breast Cancer Drug: Cyclophosphamide
Drug: Docetaxel
Drug: Gemcitabine
Drug: Paclitaxel
Drug: Doxorubicin
Phase 3

Verified by National Surgical Adjuvant Breast and Bowel Project (NSABP) June, 2013

Sponsored by: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Information provided by: National Surgical Adjuvant Breast and Bowel Project (NSABP) identifier: NCT00093795

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio 44131
United States

Sandra M. Swain, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site